Table 1.
Laboratory-acquired brucellosis cases reported to CDC (2008–2010)
| Case | Risk | Date of last exposure (mo/day/yr) | Incubation period | PEP |
Date of diagnosis (mo/yr or mo/day/yr) | Serologic titer (wk[s])a | Culture result (species) | |
|---|---|---|---|---|---|---|---|---|
| Begun | Completed | |||||||
| 1 | Unkb | Unk | Unk | NAc | NA | 8/08 | Not available | + (B. melitensis) |
| 2 | Low | 7/14/09 | 19 wks | 7/27/09 | Yesd | 12/11/09 | <1:20 (3, 5); 1:1,280 (23) | + (B. suis) |
| 3 | High | 11/3/09e | 29 wks | NA | NA | 6/6/10 | Not available | + (B. suis) |
| 4 | Unk | 11/3/09e | 19 wks | NA | NA | 6/11/10 | 1:640 (26) | No growth |
| 5 | High | 6/2/10 | 17 wks | NA | NA | 10/18/10 | <1:20 (4, 6, 8, 10) 1:2,560 (20) | + (B. suis) |
a
A titer of ≥1:160 in one or more serum specimens or a 4-fold rise in titer, is considered a presumptive or definitive evidence of infection, respectively (21).
b
Unk, unknown.
c
NA, not available.
d
Case 2 was prescribed 3 weeks of doxycycline and rifampin; good compliance was reported.
e
Exposures may have also occurred in January, March, and October 2009.